5 FEBRUARY 2020
By Nick Sundich
Gastrointestinal diseases are among the most inconvenient types of illnesses to have, and not just because they may have you running to the loo every five minutes.
The field covers many diseases like Irritable Bowel Syndrome (IBS), Crohn’s Disease and colon cancer.
And the symptoms of these diseases are a punishment in themselves including internal pain, bloating and diarrhoea.
But fear not, a handful of ASX small caps are developing treatments for these diseases.
One is Anatara Lifescience (ASX:ANR) which not only targets humans but animals as well.
Antara’s human asset is a dietary supplement it calls Gastrointestinal ReProgramming (GaRP). GaRP targets gut inflammation by inhibiting pro-inflammatory proteins.
Anatara says pre-clinical evidence has shown it has a significant impact, but a clinical trial on humans will only begin next quarter.
Meanwhile, it’s animal health asset, Detach, attacks scour in piglets. The company is currently looking for a partner to licence and commercialise Detatch.
Please click on the link below for the full article: